文献速递类风湿关节炎

类风湿关节炎改善病情抗风湿药与痴呆发病风险的关联:一项系统评价与荟萃分析

Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis.
PubMed 文献 · RMD Open · 2024-02-27

该系统评价与荟萃分析纳入14项观察性研究、共940442例类风湿关节炎患者,评估改善病情抗风湿药与痴呆发病风险的关联。汇总结果显示,生物制剂改善病情抗风湿药总体较传统合成改善病情抗风湿药与痴呆风险降低相关(RR 0.76,95%CI 0.72至0.80),而传统合成改善病情抗风湿药总体未观察到显著保护效应。作者认为需开展对照临床试验检验肿瘤坏死因子抑制剂的神经保护潜力。

要点

  • 生物制剂改善病情抗风湿药总体较传统合成改善病情抗风湿药与痴呆风险降低相关(RR 0.76,95%CI 0.72至0.80)。
  • 肿瘤坏死因子抑制剂与非肿瘤坏死因子生物制剂均与痴呆风险降低相关(RR 0.76)。
  • 传统合成改善病情抗风湿药总体、甲氨蝶呤、羟氯喹较未使用者未见显著效应,柳氮磺吡啶与风险升高相关(RR 1.27)。

核心结论

  • 类风湿关节炎患者使用生物制剂改善病情抗风湿药与痴呆风险降低相关,而传统合成改善病情抗风湿药未观察到保护效应。
  • 作者认为需开展肿瘤坏死因子抑制剂的对照临床试验以检验其神经保护潜力。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、EMBASE和Cochrane Library电子数据库。
  • 纳入评估类风湿关节炎中改善病情抗风湿药与痴呆关联的观察性研究,共14项研究、940442例类风湿关节炎患者。
  • 汇总统计量采用风险比(RR)及95%CI,证据确定性采用推荐分级的评估、制定与评价(GRADE)系统判定。

主要发现

  • 使用生物制剂改善病情抗风湿药总体者较使用传统合成改善病情抗风湿药者发生痴呆的汇总RR为0.76(95%CI 0.72至0.80)。
  • 肿瘤坏死因子抑制剂者发生痴呆的RR为0.76(95%CI 0.71至0.82),非肿瘤坏死因子生物制剂者RR为0.76(95%CI 0.70至0.83)。
  • 不同类型肿瘤坏死因子抑制剂间存在显著亚组效应:依那西普RR 0.58(95%CI 0.53至0.65)、阿达木单抗RR 0.65(95%CI 0.59至0.72)、英夫利西单抗RR 0.80(95%CI 0.72至0.88),组间p=0.002。
  • 与传统合成改善病情抗风湿药未使用者或研究性治疗者相比,传统合成改善病情抗风湿药总体(RR 0.84,95%CI 0.59至1.20)、甲氨蝶呤(RR 0.78,95%CI 0.54至1.12)、羟氯喹(RR 0.95,95%CI 0.63至1.44)对痴呆发病率未见显著效应。
  • 柳氮磺吡啶较未使用者与痴呆风险升高相关(RR 1.27,95%CI 1.06至1.50)。

关键数值与推荐

  • 生物制剂改善病情抗风湿药总体 vs 传统合成改善病情抗风湿药:痴呆汇总RR 0.76(95%CI 0.72至0.80)。
  • 肿瘤坏死因子抑制剂:RR 0.76(95%CI 0.71至0.82);非肿瘤坏死因子生物制剂:RR 0.76(95%CI 0.70至0.83)。
  • 依那西普RR 0.58(95%CI 0.53至0.65)vs 阿达木单抗RR 0.65(95%CI 0.59至0.72)vs 英夫利西单抗RR 0.80(95%CI 0.72至0.88),组间p=0.002。
  • 传统合成改善病情抗风湿药总体RR 0.84(95%CI 0.59至1.20)、甲氨蝶呤RR 0.78(95%CI 0.54至1.12)、羟氯喹RR 0.95(95%CI 0.63至1.44),均未达统计学显著。
  • 柳氮磺吡啶RR 1.27(95%CI 1.06至1.50)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出需开展肿瘤坏死因子抑制剂的对照临床试验以检验其神经保护潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dysregulation of several inflammatory cytokines including tumour necrosis factor (TNF) in dementia patients has also been identified as a key factor in the pathogenesis of rheumatoid arthritis (RA). We aimed to investigate the association of disease-modifying antirheumatic drugs (DMARDs) therapy for RA with risk of incident dementia. METHODS: Electronic database searches of PubMed, EMBASE and Cochrane Library were performed. Observational studies that assessed the association of dementia with DMARDs in RA were included. Pooled risk ratios (RRs) with 95% CIs were used as summary statistic. The certainty of evidence was judged by using the Grading of Recommendations Assessment, Development and Evaluation system. RESULTS: Overall, 14 studies involving 940 442 patients with RA were included. Pooled RR for developing dementia was 0.76 (95% CI 0.72 to 0.80) in patients taking biological DMARDs overall versus those taking conventional synthetic DMARDs, with 24% for TNF inhibitors (RR 0.76, 95% CI 0.71 to 0.82), 24% for non-TNF biologics (RR 0.76, 95% CI 0.70 to 0.83), separately. There was a significant subgroup effect among different types of TNF inhibitors (RR 0.58 [95%CI 0.53 to 0.65], 0.65 [95% CI 0.59 to 0.72], 0.80 [95% CI 0.72 to 0.88] for etanercept, adalimumab, infliximab, respectively; p value between groups=0.002). However, compared with non-users of DMARDs or investigative treatment, no significant effect on dementia incidence was observed in those receiving conventional synthetic DMARDs overall (RR 0.84, 95% CI 0.59 to 1.20), methotrexate (RR 0.78, 95% CI 0.54 to 1.12), hydroxychloroquine (RR 0.95, 95% CI 0.63 to 1.44), except for sulfasalazine (RR 1.27, 95% CI 1.06 to 1.50). CONCLUSIONS: Biological DMARDs for RA are associated with decreased dementia risk, while protective effect is not observed in conventional synthetic DMARDs. Controlled clinical trials on TNF inhibitors are necessary to test their neuroprotective potentials.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Xie W, Hou Y, Xiao S, et al. Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis. RMD Open. 2024. PMID: 38413170. doi:10.1136/rmdopen-2023-004016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。